Healthcare
Live Price
Offline$6.42
+3.72% today
1Y Change
+129.32%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Taysha Gene Therapies, Inc. (TSHA) is a Healthcare stock with a market cap of $1.58B and listed on NASDAQ. The stock last traded around $6.42 and up 129.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +17.3%, EPS growth of +5.6%, a dividend yield of 0.0%. What stands out right now is revenue +17.3%, EPS +5.6%, free cash flow -15.0% with operating margin -1130.6% and ROIC -34.9%. Valuation already assumes a fairly strong business story at price/sales 162.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TSHA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSHA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TSHA Max Drawdown
-31.13%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TSHA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$174.5M
-5.1% YoY
Free Cash Flow
-$138.6M
-22.4% YoY
Revenue Growth
+17.3%
EPS Growth
+5.6%
Gross Margin
94.0%
Net Margin
-1115.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 10M | 8M | 15M | 3M | 0 |
| Gross Profit | 9M | 8M | 15M | 15K | 0 |
| Operating Income | -110M | -91M | -72M | -126M | -173M |
| EBITDA | -109M | -88M | -105M | -160M | -173M |
| Net Income | -109M | -89M | -112M | -166M | -175M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 320M | 139M | 144M | 88M | 149M |
| Total Assets | 343M | 160M | 173M | 126M | 214M |
| Total Liabilities | 96M | 89M | 98M | 125M | 119M |
| Shareholder Equity | 247M | 72M | 75M | 949K | 95M |
| Total Debt | 18M | 63M | 61M | 60M | 63M |
| Net Debt | -302M | -76M | -83M | -28M | -86M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
117M
-32.4% YoY
Capital Expenditures
22M
+13.3% YoY
Free Cash Flow
139M
-22.4% YoY
Key ratios
Gross Margin
94.0%
Operating Margin
-1130.6%
Net Margin
-1115.3%
ROE
-56.6%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.